Curis Inc (CRIS)

$3.79

-0.01

(-0.26%)▲

Market is closed - opens 8 PM, 20 Nov 2024

Performance

  • $3.63
    $3.92
    $3.79
    downward going graph

    4.22%

    Downside

    Day's Volatility :7.32%

    Upside

    3.23%

    downward going graph
  • $3.51
    $17.49
    $3.79
    downward going graph

    7.39%

    Downside

    52 Weeks Volatility :79.93%

    Upside

    78.33%

    downward going graph

Returns

PeriodCuris IncSector (Health Care)Index (Russel 2000)
3 Months
-13.86%
-8.6%
0.0%
6 Months
-63.97%
-3.3%
0.0%
1 Year
-55.2%
9.4%
0.0%
3 Years
-96.28%
6.2%
-24.5%

Highlights

Market Capitalization
23.7M
Book Value
$3.34
Earnings Per Share (EPS)
-7.77
PEG Ratio
0.0
Wall Street Target Price
21.0
Profit Margin
0.0%
Operating Margin TTM
-491.44%
Return On Assets TTM
-45.97%
Return On Equity TTM
-372.68%
Revenue TTM
10.2M
Revenue Per Share TTM
1.76
Quarterly Revenue Growth YOY
15.9%
Gross Profit TTM
-33.4M
EBITDA
-49.3M
Diluted Eps TTM
-7.77
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-6.81
EPS Estimate Next Year
-3.81
EPS Estimate Current Quarter
-1.91
EPS Estimate Next Quarter
-1.5

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Curis Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 454.09%

Current $3.79
Target $21.00

Company Financials

FY18Y/Y Change
Revenue
10.4M
↑ 5.35%
Net Income
-32.6M
↓ 38.9%
Net Profit Margin
-312.38%
↑ 226.28%
FY19Y/Y Change
Revenue
10.0M
↓ 4.07%
Net Income
-36.8M
↑ 12.98%
Net Profit Margin
-367.89%
↓ 55.51%
FY20Y/Y Change
Revenue
10.8M
↑ 8.31%
Net Income
-34.9M
↓ 5.22%
Net Profit Margin
-321.93%
↑ 45.96%
FY21Y/Y Change
Revenue
10.6M
↓ 1.72%
Net Income
-50.6M
↑ 45.18%
Net Profit Margin
-475.54%
↓ 153.61%
FY22Y/Y Change
Revenue
10.2M
↓ 4.57%
Net Income
-60.3M
↑ 19.12%
Net Profit Margin
-593.62%
↓ 118.08%
FY23Y/Y Change
Revenue
10.0M
↓ 1.37%
Net Income
-47.4M
↓ 21.4%
Net Profit Margin
-473.04%
↑ 120.58%
Q2 FY23Q/Q Change
Revenue
2.2M
↓ 4.35%
Net Income
-12.0M
↑ 4.09%
Net Profit Margin
-544.42%
↓ 44.16%
Q3 FY23Q/Q Change
Revenue
2.8M
↑ 28.95%
Net Income
-12.2M
↑ 1.84%
Net Profit Margin
-429.97%
↑ 114.45%
Q4 FY23Q/Q Change
Revenue
2.7M
↓ 4.84%
Net Income
-11.8M
↓ 3.29%
Net Profit Margin
-436.94%
↓ 6.97%
Q1 FY24Q/Q Change
Revenue
2.1M
↓ 22.63%
Net Income
-11.9M
↑ 0.81%
Net Profit Margin
-569.32%
↓ 132.38%
Q2 FY24Q/Q Change
Revenue
2.5M
↑ 22.05%
Net Income
-11.8M
↓ 0.61%
Net Profit Margin
-463.59%
↑ 105.73%
Q3 FY24Q/Q Change
Revenue
2.9M
↑ 15.12%
Net Income
-10.1M
↓ 14.5%
Net Profit Margin
-344.32%
↑ 119.27%
FY18Y/Y Change
Total Assets
37.4M
↓ 49.37%
Total Liabilities
41.9M
↓ 15.95%
FY19Y/Y Change
Total Assets
35.1M
↓ 6.04%
Total Liabilities
69.0M
↑ 64.87%
FY20Y/Y Change
Total Assets
204.4M
↑ 482.1%
Total Liabilities
73.7M
↑ 6.77%
FY21Y/Y Change
Total Assets
162.3M
↓ 20.58%
Total Liabilities
71.6M
↓ 2.84%
FY22Y/Y Change
Total Assets
108.8M
↓ 32.93%
Total Liabilities
62.3M
↓ 12.99%
FY23Y/Y Change
Total Assets
77.3M
↓ 29.0%
Total Liabilities
57.6M
↓ 7.52%
Q2 FY23Q/Q Change
Total Assets
84.3M
↓ 10.83%
Total Liabilities
58.1M
↑ 0.22%
Q3 FY23Q/Q Change
Total Assets
90.0M
↑ 6.72%
Total Liabilities
60.4M
↑ 3.96%
Q4 FY23Q/Q Change
Total Assets
77.3M
↓ 14.11%
Total Liabilities
57.6M
↓ 4.59%
Q1 FY24Q/Q Change
Total Assets
62.0M
↓ 19.74%
Total Liabilities
52.6M
↓ 8.77%
Q2 FY24Q/Q Change
Total Assets
50.4M
↓ 18.72%
Total Liabilities
51.1M
↓ 2.77%
Q3 FY24Q/Q Change
Total Assets
42.5M
↓ 15.75%
Total Liabilities
51.2M
↑ 0.2%
FY18Y/Y Change
Operating Cash Flow
-30.1M
↓ 37.82%
Investing Cash Flow
21.4M
↓ 688.82%
Financing Cash Flow
-6.0M
↓ 109.28%
FY19Y/Y Change
Operating Cash Flow
-26.2M
↓ 12.84%
Investing Cash Flow
-4.5M
↓ 120.85%
Financing Cash Flow
23.3M
↓ 490.39%
FY20Y/Y Change
Operating Cash Flow
-25.7M
↓ 1.78%
Investing Cash Flow
-49.0M
↑ 1000.72%
Financing Cash Flow
188.8M
↑ 711.37%
FY21Y/Y Change
Operating Cash Flow
-37.6M
↑ 46.16%
Investing Cash Flow
-47.9M
↓ 2.35%
Financing Cash Flow
-4.2M
↓ 102.21%
FY22Y/Y Change
Operating Cash Flow
-54.3M
↑ 44.44%
Investing Cash Flow
33.0M
↓ 168.95%
Financing Cash Flow
867.0K
↓ 120.78%
Q2 FY23Q/Q Change
Operating Cash Flow
-7.9M
↓ 35.5%
Investing Cash Flow
-3.2M
↓ 112.02%
Financing Cash Flow
-852.0K
↓ 57.53%

Technicals Summary

Sell

Neutral

Buy

Curis Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Curis Inc
Curis Inc
-28.89%
-63.97%
-55.2%
-96.28%
-87.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-23.12%
-24.58%
-7.12%
15.69%
116.3%
Biontech Se
Biontech Se
-4.64%
15.06%
7.66%
-66.93%
422.85%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-19.77%
55.93%
41.76%
25.27%
116.5%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.29%
0.48%
25.55%
146.84%
108.31%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Curis Inc
Curis Inc
NA
NA
0.0
-6.81
-3.73
-0.46
NA
3.34
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.73
18.73
1.13
44.87
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.02
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.22
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Curis Inc
Curis Inc
Buy
$23.7M
-87.61%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$83.2B
116.3%
18.73
33.61%
Biontech Se
Biontech Se
Buy
$23.9B
422.85%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
116.5%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.3B
108.31%
32.84
-4.51%

Insights on Curis Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 2.08M → 2.93M (in $), with an average increase of 15.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -11.87M → -10.09M (in $), with an average increase of 8.8% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 41.8% return, outperforming this stock by 97.0%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 29.4% return, outperforming this stock by 125.7%

Institutional Holdings

  • Maverick Capital Ltd

    9.67%

  • M28 Capital Management LP

    7.01%

  • Kingdon Capital Management LLC

    5.74%

  • Vanguard Group Inc

    4.56%

  • CM Management, LLC

    1.99%

  • Point72 Asset Management, L.P.

    1.80%

Company Information

curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl

Organization
Curis Inc
Employees
49
CEO
Mr. James E. Dentzer
Industry
Health Technology

FAQs